This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignees: Institut Pasteur, Assistance Publique-Hopitaux De Paris, National Institute of Health and Medical Research. Active years: 2009-2012.
Company Filing History:
2 out of 897 
1 out of 331 
1 out of 1,853 
Years Active: 2009-2012
Title: Etienne Vilmer: Innovator in Immunogenic Peptides
Introduction
Etienne Vilmer is a notable inventor based in Paris, France. He has made significant contributions to the field of immunology, particularly in the development of therapeutic vaccines. With a total of 2 patents, his work focuses on optimizing immunogenic peptides for the treatment of leukemia in humans.
Latest Patents
Vilmer's latest patents include innovations related to mutated immunogenic peptides derived from the R9M sequence. These inventions concern the optimization of the wild R9M peptide and its application for therapeutic and preventive vaccination against leukemia. The patents detail the mutated immunogenic peptides derived from the human TEL/AML1 fusion protein, which includes the wild R9M peptide sequence Arg-Ile-Ala-Glu-Cys-Ile-Leu-Gly-Met. Additionally, the patents cover polynucleotides coding for these mutated peptides, cellular expression vectors, and antibodies that can bind to the peptides or polynucleotides. The inventions aim to prepare vaccines and anti-tumoral medicines, enhancing the immune response in humans both in vitro and in vivo.
Career Highlights
Throughout his career, Etienne Vilmer has worked with prestigious institutions such as Institut Pasteur and the National Institute of Health and Medical Research. His research has significantly advanced the understanding of immunogenic peptides and their therapeutic applications.
Collaborations
Vilmer has collaborated with notable colleagues in his field, including Hüseyin Firat and Pierre Langlade-Demoyan. These collaborations have further enriched his research and contributions to immunology.
Conclusion
Etienne Vilmer's innovative work in the field of immunogenic peptides has the potential to transform therapeutic approaches to leukemia. His patents reflect a commitment to advancing medical science and improving patient outcomes.